As shown by AstraZeneca in nature reviews*, one third of safety failures along the drug discovery process is linked to CNS toxicity uncovered in clinical trials. To avoid this attrition, the potential neurotoxicity of any drug going through the blood brain barrier (BBB) needs to be assessed in the very early stages of new chemical entities (NCE) research. Neurotoxicity assays can be performed on the SH-SY5Y human cell line by using High-Content Screening (HCS) technologies. The present study was performed using classical 2D and 3D culture protocols. In this poster, 2D results and preliminary 3D culture results on multiple reference compounds are depicted.
View and download on Slideshare (low quality) : https://www.slideshare.net/hcspharma/in-vitro-dermocosmetology-high-content-analysis-approach-using-human-primary-keratinocytes-and-fibroblasts
Ask for high quality link by putting your email below
Cell biology is part of the R&D activity in dermocosmetology, as providers of active extracts or pure compounds have to demonstrate their efficacy and safety. At HCS Pharma, we are developing new dermocosmetology assays on relevant cellular models, like human primary keratinocytes and human primary fibroblasts, using our automated platform and high content analysis system. Through the use of 96 or 384 wells plates combined with process automation, we constantly increase the throughput in order to allow proof of concept assays of one or several compounds up to the screening of large compounds libraries, for single endpoint or live cells analysis to multiplexed phenotypic screening.
